A Retrospective Analysis of the Efficacy and Safety of Imatinib for Advanced Gastrointestinal Stromal Tumor in Elderly Patients
Cancer Medicine · 2025
DOI: 10.1002/cam4.71338 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Takahito Awatsu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Gastrointestinal Stromal Tumors, Imatinib Mesylate, Antineoplastic Agents, Gastrointestinal Neoplasms. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Gastrointestinal stromal tumor ( GIST ) occurs predominantly in the elderly population. However, clinical data on the outcomes of treatment with imatinib in elderly patients are limited. The aim of this study was to determine the efficacy and safety of imatinib for advanced GIST in the elderly population compared with the non‐elderly population.
Methods
We analyzed the clinical data of patients who received imatinib as first‐line treatment for advanced GIST at our hospital between January 2010 and July 2023. Progression‐free survival ( PFS ), overall survival ( OS ), and adverse events were compared between elderly patients (age ≥ 70 years, E group) and non‐elderly patients (age < 70 years, NE group).
Result
Data of 91 patients (E group, n = 32; NE group, n = 59) with a median follow‐up of 39.8 months were analyzed. A significantly higher proportion of patients in the E group required a reduced starting dose of imatinib (34% vs. 2%, p < 0.001). Median PFS was 29.4 months in the E group and 60.0 months in the NE group (hazard ratio [ HR ] 2.04, p = 0.04, log‐rank test); median OS was 91.5 months in the E group and not reached in the NE group ( HR 2.72, p = 0.03, log‐rank test). Multivariable analysis identified age as an independent prognostic factor for PFS ( HR 2.26, p = 0.03) and a trend towards worse OS with increasing age ( HR 2.93, p = 0.06). Grade 2 or higher non‐hematological adverse events were more prevalent in the E group (78% vs. 32%, p < 0.001).
Conclusion
Imatinib is an effective treatment for advanced GIST in elderly patients. However, elderly patients were associated with poorer efficacy and a Higher incidence of toxicities due to imatinib compared with non‐elderly patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
- Department of Gastroenterology, Juntendo University, School of Medicine, Tokyo, Japan.
- Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan.
- Department of Pathophysiological Research and Therapeutics for Gastrointestinal Disease, Juntendo University, School of Medicine, Tokyo, Japan.
ORCID-Profile: Takahito Awatsu, Kengo Nagashima
Zitieren
APA
Awatsu, T., Hirano, H., Nagashima, K., Hirose, T., Okita, N., Shoji, H., Takashima, A., Nagahara, A., & Kato, K. (2025). A Retrospective Analysis of the Efficacy and Safety of Imatinib for Advanced Gastrointestinal Stromal Tumor in Elderly Patients. Cancer Medicine. https://doi.org/10.1002/cam4.71338
Vancouver
Awatsu T, Hirano H, Nagashima K, Hirose T, Okita N, Shoji H, et al. A Retrospective Analysis of the Efficacy and Safety of Imatinib for Advanced Gastrointestinal Stromal Tumor in Elderly Patients. Cancer Medicine. 2025. doi:10.1002/cam4.71338
BibTeX
@article{Awatsu2025,
author = {Awatsu, Takahito and Hirano, Hidekazu and Nagashima, Kengo and Hirose, Toshiharu and Okita, Natsuko and Shoji, Hirokazu and Takashima, Atsuo and Nagahara, Akihito and Kato, Ken},
title = {A Retrospective Analysis of the Efficacy and Safety of Imatinib for Advanced Gastrointestinal Stromal Tumor in Elderly Patients},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71338}
}
EUVIMED